Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cns Pharmaceuticals Inc (CNSP)

Cns Pharmaceuticals Inc (CNSP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,117
  • Shares Outstanding, K 16,450
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,880 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6201 +8.64%
on 07/14/20
2.3600 -25.42%
on 07/29/20
+0.0700 (+4.14%)
since 07/13/20
3-Month
1.5900 +10.69%
on 07/13/20
3.3400 -47.31%
on 06/10/20
-1.0000 (-36.23%)
since 05/01/20

Most Recent Stories

More News
CNS Pharmaceuticals to Provide Second Quarter 2020 Business Update on Thursday, August 13, 2020

, /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced that...

CNSP : 1.7500 (-1.13%)
CNS Pharmaceuticals Recognizes Glioblastoma Awareness Day

, /PRNewswire/ -- ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system,...

CNSP : 1.7500 (-1.13%)
Clinical Trials for Evolving Targeted Therapies Fueling Gains for Brain Tumor Therapeutics Market

, /PRNewswire/ -- An array of reports have projected that the global brain tumor drugs market will continue to rise for the next several years. One earlier from said that the Global Brain Tumor Therapeutics...

CNSP : 1.7500 (-1.13%)
RIGL : 2.51 (+0.40%)
INMB : 10.13 (+2.01%)
MRK : 82.74 (+0.07%)
VBIV : 3.76 (+7.43%)
CNS Pharmaceuticals Completes Drug Product Manufacturing Strategy for Berubicin

, /PRNewswire/ -- (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous...

CNSP : 1.7500 (-1.13%)
CNS To Present at the Life Sciences Investor Forum

, /PRNewswire/ -- CNS Pharmaceuticals, Inc., (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers...

CNSP : 1.7500 (-1.13%)
CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin

, ,  2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic...

CNSP : 1.7500 (-1.13%)
CNS Announces Highlights from Annual Meeting of Shareholders

, /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers...

CNSP : 1.7500 (-1.13%)
CNS Pharmaceuticals Announces Sponsored Research Agreement with MD Anderson for Potential Cancer Treatment Technologies

, /PRNewswire/ --  ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system,...

CNSP : 1.7500 (-1.13%)
CNS Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020

, /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers...

CNSP : 1.7500 (-1.13%)
Nasdaq Scheduled Resumption in CNS Pharmaceuticals Inc.

The Nasdaq Stock Market (Nasdaq: NDAQ) announced that trading in CNS Pharmaceuticals Inc. (Nasdaq: CNSP) is scheduled to resume on Thursday, May 28, 2020, at 7:00 a.m. Eastern Time. Trading in the company's...

NDAQ : 130.12 (-0.23%)
CNSP : 1.7500 (-1.13%)
Trade CNSP with:

Business Summary

CNS Pharmaceuticals Inc. is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. The company's lead drug includes Berubicin, for the treatment of Glioblastoma Multiforme and potentially for other CNS malignancies. CNS Pharmaceuticals Inc. is...

See More

Key Turning Points

2nd Resistance Point 1.9248
1st Resistance Point 1.8474
Last Price 1.7500
1st Support Level 1.7063
2nd Support Level 1.6426

See More

52-Week High 5.6899
Fibonacci 61.8% 3.9970
Fibonacci 50% 3.4741
Fibonacci 38.2% 2.9511
Last Price 1.7500
52-Week Low 1.2582

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar